News
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61
24 Apr 24
News, Price Target, Analyst Ratings
RBC Capital Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces Price Target of $77
22 Apr 24
News, Price Target, Initiation, Analyst Ratings
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
16 Apr 24
News, Price Target, Reiteration, Analyst Ratings
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
15 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
15 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
15 Apr 24
Biotech, News, Health Care, Movers, Trading Ideas, General
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
15 Apr 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Ultragenyx Reveal New Data From Phase 1/2 Study Of GTX-102 For Treatment Of Angelman Syndrome
15 Apr 24
News
Ultragenyx Announces Update To Conference Call Timing To Discuss New Data From GTX-102 In Patients With Angelman Syndrome; Conference Call Now Scheduled For Monday, April 15 At 8:00 a.m. ET
12 Apr 24
Biotech, News, Events, General
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
5 Apr 24
Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target
5 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Mark Cuban Is Bullish On AI Minting 'World's First Trillionaire'...And His Crypto Portfolio Backs It Up
5 Apr 24
Cryptocurrency, News, Top Stories
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
18 Mar 24
Analyst Ratings
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Announces $107 Price Target
27 Feb 24
News, Price Target, Analyst Ratings
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $111
21 Feb 24
News, Price Target, Analyst Ratings
Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $48
16 Feb 24
News, Price Target, Analyst Ratings
Ultragenyx Pharmaceutical Q4 EPS $(1.52) Beats $(1.62) Estimate, Sales $127.39M Beat $119.38M Estimate
15 Feb 24
Earnings, News
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
15 Feb 24
Analyst Ratings
Press releases
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
25 Apr 24
News, Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 Apr 24
Markets, Press Releases
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
15 Apr 24
News, Press Releases
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
12 Apr 24
News, Health Care, Press Releases
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
12 Apr 24
News, Health Care, Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 Mar 24
Markets, Press Releases
Ultragenyx to Participate at Investor Conferences in March
27 Feb 24
News, Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 Feb 24
Press Releases
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
15 Feb 24
Earnings, Press Releases
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
8 Feb 24
News, Press Releases
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
5 Feb 24
Health Care, Press Releases